Phase III
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial on Sunday that showed its triple combination therapy PT010 outperformed its dual-therapy rivals eight of nine times.
The Morgan Stanley Global Healthcare Conference ran from September 12 through 14, with numerous biopharma companies making presentations, updating their operations and pipeline activities. Here’s a look a few of the highlights.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA’s decision to delay a ruling for its Parkinson’s disease treatment.
Shares of San Diego-based Vital Therapies have plunged more than 88 percent in premarket trading after the company announced that its Phase III liver disease treatment failed to improve overall survival in patients.
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints
Late-stage trial results show that a combination of Bavencio (avelumab) and Inlyta (axitinib) significantly improved progression-free survival in previously untreated patients with advanced renal cell carcinoma.
Shares of Indiana-based Endocyte have slipped more than 3 percent this morning after the company announced the U.S. Food and Drug Administration accepted radiographic progression-free survival as an alternative primary endpoint in its Phase III VISION trial.
Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population
Eli Lilly and Company and its wholly-owned subsidiary Avid Radiopharmaceuticals, announced the successful Phase III trial of a Positron Emission Tomography (PET) imaging agent, flortaucipr F 18, in identifying tau in the brains of late-stage Alzheimer’s patients.
PRESS RELEASES